Skip to main content
HR 828 108th Congress House Health Clinical trials Commerce Congress Congressional investigations Congressional reporting requirements Drug approvals Drug industry Drugs Economics and Public Finance Federal aid to research Generic drugs Government Operations and Politics Intellectual property Medical research Patents Pharmaceutical research Prescription pricing Profit Research and development

Pharmaceutical Fiscal Accountability Act of 2003

Introduced: February 13, 2003 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 108th Congress ended
It never became law before the 108th Congress (2003–2004) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 26, 2003
Referred to the Subcommittee on Health.
Feb 13, 2003
Referred to the House Committee on Energy and Commerce.
Feb 13, 2003
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service
Pharmaceutical Fiscal Accountability Act of 2003 - Amends the Federal Food, Drug, and Cosmetic Act to treat certain subsequent certified abbreviated new drug applications as if they were the first such application and therefore entitled to a period of 180 day generic drug exclusivity. (Abbreviated new drug applications are filed where the new drugs uses or active ingredient(s) are the same as those for a previously approved drug, also known as a "listed drug.")

Amends the Public Health Service Act to require the Director of the National Institutes of Health to support qualifying clinical research on the development of new drugs at designated small public or private entities. Emphasizes drug research which has the potential to make a significant contribution for the prevention, diagnosis, or treatment of a disease which has not received significant Federal funding. Entitles the Director to five percent of the profits from sales during the patent period.

Requires the Comptroller General to study and report to Congress on the effects of: (1) Federal funding on the costs of research and the pricing of prescription drugs; and (2) pharmaceutical patent extensions and market exclusivity periods on delays in introducing generic versions.

What's happening now February 26, 2003

Referred to the Subcommittee on Health.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Democratic 1
D
Norton, Eleanor Holmes
District of Columbia · Feb 13, 2003
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 828: Pharmaceutical Fiscal Accountability Act of 2003. 108th Congress. Open America. https://openamerica.io/bill/108-HR-828/
MLA
"H.R. 828: Pharmaceutical Fiscal Accountability Act of 2003." 108th Congress, 2026, Open America, https://openamerica.io/bill/108-HR-828/.
Bluebook (legal)
H.R. 828, 108th Cong. (2026), https://openamerica.io/bill/108-HR-828/.
Markdown link
[H.R. 828: Pharmaceutical Fiscal Accountability Act of 2003](https://openamerica.io/bill/108-HR-828/)
Report a problem